# Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

> **NCT02294396** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 649 (actual)

## Conditions studied

- Overactive Bladder (OAB)

## Interventions

- **DRUG:** Mirabegron tablet
- **DRUG:** Solifenacin tablet
- **DRUG:** Propiverine tablet
- **DRUG:** Imidafenacin tablet
- **DRUG:** Tolterodine capsule

## Key facts

- **NCT ID:** NCT02294396
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-28
- **Primary completion:** 2016-09-07
- **Final completion:** 2016-09-07
- **Target enrollment:** 649 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02294396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02294396, "Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02294396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*